Medium- or High-dose Omeprazole Plus Amoxicillin Eradicates Helicobacter Pylori in Gastric Ulcer Disease
Overview
Authors
Affiliations
Objective: To compare the efficacy of two omeprazole/amoxicillin regimens concerning Helicobacter pylori eradication, ulcer healing, pain relief, and safety in patients with gastric ulcer disease.
Methods: In a prospective, single-blind, single-center study, 70 patients with active, H. pylori-positive (histology and/or culture) gastric ulcers were randomly treated with either omeprazole 20 mg b.i.d. plus amoxicillin 1 g b.i.d. (group I; n = 35) or with omeprazole 40 mg b.i.d. plus amoxicillin 1 g b.i.d. over 2 wk, followed by full dose ranitidine for another 4 wk. Patients were investigated clinically and endoscopically prior to treatment and after 6 wk, including the assessment of H. pylori status by means of urease test, specific culture, and histology.
Results: Patients of group I and II had similar demographic and clinical characteristics. Three patients were lost to follow-up. The overall proportion of H. pylori eradication was 88.1% (group I, 91.2%; group II, 84.8%, p = NS). The ulcer healing rate was 79.1% after 6 wk, 92.5% after 10 wk, and 100% after 6 months, without a statistically significant difference between the study groups. Complete pain relief occurred after a median of 2 days (group I) and 1.5 days (group II, p = NS), respectively. Six patients (9.0%) complained of side effects that led to discontinuation of amoxicillin treatment in three patients (4.5%).
Conclusions: Omeprazole plus amoxicillin is a highly effective and well-tolerated therapy regimen to eradicate H. pylori from the gastric mucosa of patients with gastric ulcer disease. In addition, the results clearly suggest that medium- and high-dose omeprazole schedules are equally effective with regard to bacterial eradication, ulcer healing, pain relief, and safety in gastric ulcers. Thus, medium- and not high-dose omeprazole plus amoxicillin should be the treatment regimen of first choice to eradicate H. pylori in gastric ulcer disease.
Novel therapeutic regimens against : an updated systematic review.
Huang T, Cao Y, Cao L Front Microbiol. 2024; 15:1418129.
PMID: 38912349 PMC: 11190606. DOI: 10.3389/fmicb.2024.1418129.
Graham D, Javed S, Keihanian S, Abudayyeh S, Opekun A J Gastroenterol. 2010; 45(8):816-20.
PMID: 20195646 DOI: 10.1007/s00535-010-0220-x.
Unge P, Jonsson B, Stalhammar N Pharmacoeconomics. 1995; 8(5):410-27.
PMID: 10160075 DOI: 10.2165/00019053-199508050-00005.
A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.
Hackelsberger A, Malfertheiner P Drug Saf. 1996; 15(1):30-52.
PMID: 8862962 DOI: 10.2165/00002018-199615010-00003.
Short-term treatment of gastric ulcer. A meta-analytical evaluation of blind trials.
Di Mario F, Battaglia G, Leandro G, Grasso G, Vianello F, Vigneri S Dig Dis Sci. 1996; 41(6):1108-31.
PMID: 8654142 DOI: 10.1007/BF02088227.